HRT Financial’s 10x Genomics TXG Stock Holding History

HRT Financial’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.72M	Sell	80,927 -100,225	-55%	-$2M	﹤0.01%	1718
2025 Q4	$2.95M	Buy	+181,152	New	+$2.74M	0.01%	1052
2024 Q4	–	Sell	-38,721	Closed	-$874K	–	3272
2024 Q3	$874K	Buy	+38,721	New	+$801K	﹤0.01%	1308
2024 Q1	–	Sell	-40,050	Closed	-$2.24M	–	3114
2023 Q4	$2.24M	Buy	+40,050	New	+$1.74M	0.02%	602
2023 Q3	–	Sell	-38,178	Closed	-$2.13M	–	3119
2023 Q2	$2.13M	Sell	38,178 -39,723	-51%	-$2.15M	0.02%	587
2023 Q1	$4.35M	Buy	77,901 +71,590	+1,134%	+$3.34M	0.05%	287
2022 Q4	$229K	Buy	+6,311	New	+$206K	﹤0.01%	1885

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's TXG Position: Q1 2026 in Review

HRT Financial reduced its 10x Genomics (TXG) stake by 55% in Q1 2026, selling an estimated $2M and leaving 80,927 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

HRT Financial first reported a position in TXG in Q4 2022 and has held it in 7 quarters since. The position peaked at $4.35M in Q1 2023. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

HRT Financial held 80,927 shares of 10x Genomics worth $1.72M as of Q1 2026.
HRT Financial sold 100,225 10x Genomics shares in Q1 2026, an estimated $2M.
10x Genomics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #1718 holding.
HRT Financial first reported a position in 10x Genomics in Q4 2022 and has held it in 7 quarters since.
HRT Financial's 10x Genomics position peaked at $4.35M in Q1 2023.
329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.